Document Detail

Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats.
MedLine Citation:
PMID:  21749863     Owner:  NLM     Status:  MEDLINE    
Substantial evidences suggest that lipoxygenase-catalyzed products have a strong influence on the development and progression of human cancers. The dietary phytochemical resveratrol has become a focus of intense research owing to its roles in cancer prevention. A single tail vein injection of 7,12-dimethylbenz(a)anthracene (DMBA) was given at a dose of 0.5mg/0.2 ml oil emulsion/100g body weight at 50 days of age of female Sprague-Dawley rats. Rats were treated with resveratrol from 2 weeks before DMBA injection (5 weeks of animal age) and continued to 24 weeks of the experimentation at a dose of 100 μg/rat in the diet. We observed that resveratrol acts as a potent 5-lipoxygenase (5-LOX) inhibitor obtained from natural sources. Our result indicated that resveratrol is a strong antioxidant in reducing lipid peroxidation and preventing DNA damage. It significantly decreased the extent of DNA strand break, inhibited abnormal cell proliferation as evidenced by BrdU labeling index and also induced apoptosis in carcinogen-challenged rat mammary tissue. Increased TGF-β1 expression in resveratrol treated rats is thought to be one of the factors inducing apoptosis to suppress DMBA-induced mammary carcinogenesis.
Mary Chatterjee; Subhadeep Das; M Janarthan; Hari K Ramachandran; Malay Chatterjee
Related Documents :
3584463 - Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.
6696723 - Cell-free translation of messenger rna for chondroitin sulphate proteoglycan core prote...
3178163 - Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared t...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-07-06
Journal Detail:
Title:  European journal of pharmacology     Volume:  668     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-08-26     Completed Date:  2011-12-27     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  99-106     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Chemical Carcinogenesis and Chemoprevention Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata-700 032, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
9,10-Dimethyl-1,2-benzanthracene / toxicity*
Apoptosis / drug effects
Arachidonate 5-Lipoxygenase / metabolism*
Cell Proliferation / drug effects
Cyclin D1 / metabolism
DNA Breaks / drug effects
Gene Expression Regulation, Neoplastic / drug effects
In Situ Nick-End Labeling
Leukotriene B4 / biosynthesis
Lipid Peroxidation / drug effects
Lipoxygenase Inhibitors / pharmacology*,  therapeutic use
Mammary Glands, Animal / drug effects,  metabolism,  pathology
Mammary Neoplasms, Experimental / chemically induced*,  drug therapy*,  metabolism,  pathology
NF-kappa B / metabolism
Rats, Sprague-Dawley
Stilbenes / pharmacology*,  therapeutic use
Transforming Growth Factor beta1 / metabolism
Reg. No./Substance:
0/Lipoxygenase Inhibitors; 0/NF-kappa B; 0/Stilbenes; 0/Transforming Growth Factor beta1; 136601-57-5/Cyclin D1; 57-97-6/9,10-Dimethyl-1,2-benzanthracene; 71160-24-2/Leukotriene B4; EC 5-Lipoxygenase; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease.
Next Document:  Insights into structure-activity relationship of GABAA receptor modulating coumarins and furanocouma...